Table 1 Number of observed second primary cancers (Obs) following breast cancer, diagnosed between 1958 and 2000, standardised incidence ratios (SIRs), and 95% confidence interval (CI) among women
Second primary cancer site | Obs | SIR | 95% CI |
|---|---|---|---|
Upper aerodigestive tract | 137 | 0.89 | (0.75–1.04) |
Salivary glands | 43 | 1.67 | (1.21–2.20) |
Oesophagus | 116 | 1.57 | (1.24–1.78) |
Stomach | 686 | 1.40 | (1.30–1.51) |
Small intestine | 76 | 1.29 | (1.02–1.60) |
Colorectum | 1923 | 1.15 | (1.10–1.20) |
Liver | 451 | 0.92 | (0.84–1.01) |
Pancreas | 471 | 1.12 | (1.02–1.22) |
Lung | 717 | 1.37 | (1.27–1.47) |
Cervix | 217 | 0.92 | (0.80–1.05) |
Endometrium | 1006 | 1.54 | (1.44–1.63) |
Ovary | 712 | 1.28 | (1.19–1.38) |
Kidney | 443 | 1.31 | (1.19–1.44) |
Urinary organs | 383 | 1.10 | (0.99–1.21) |
Melanoma | 360 | 1.27 | (1.14–1.40) |
Nervous system | 367 | 1.16 | (1.05–1.28) |
Thyroid | 164 | 1.55 | (1.32–1.80) |
Endocrine glands | 270 | 1.08 | (1.96–1.22) |
Bone | 21 | 1.68 | (1.04–2.48) |
Connective tissue | 129 | 1.78 | (1.49–2.10) |
Non-Hodgkin's lymphoma | 390 | 1.13 | (1.02–1.25) |
Hodgkin's disease | 38 | 1.05 | (0.74–1.41) |
Multiple myeloma, plasmocytoma | 182 | 1.04 | (0.89–1.20) |
Leukaemia | 343 | 1.37 | (1.23–1.52) |
All the above sites | 9758 | 1.22 | (1.19–1.24) |
